|           |                       | + 48 h HDACi pretreatment |     |                       |     |                       |     |
|-----------|-----------------------|---------------------------|-----|-----------------------|-----|-----------------------|-----|
| cell line | cisplatin             | entinostat                |     | panobinostat          |     | nexturastat A         |     |
|           | IC50<br>[pIC50 ± SEM] | IC50<br>[pIC50 ± SEM]     | SF  | IC50<br>[pIC50 ± SEM] | SF  | IC50<br>[pIC50 ± SEM] | SF  |
| A2780     | 11.0                  | 4.99                      | 2.2 | 2.58                  | 5.6 | 1.44                  | 7.6 |
|           | [4.96 ± 0.01]         | [5.30 ± 0.05]             | *** | [5.59 ± 0.04]         | *** | [5.84 ± 0.06]         | *** |
| CaOV3     | 1.44                  | 0.72                      | 2.0 | 0.74                  | 2.0 | 1.33                  | 1.1 |
|           | [5.84 ± 0.01]         | [6.14 ± 0.05]             | *   | [6.13 ± 0.05]         | ns  | [5.88 ± 0.04]         | ns  |
| HEY       | 5.25                  | 1.39                      | 3.8 | 2.75                  | 1.9 | 1.28                  | 4.1 |
|           | [5.28 ± 0.01]         | [5.89 ± 0.03]             | *** | [5.56 ± 0.04]         | *   | [5.89 ± 0.04]         | *** |
| Kuramochi | 4.68                  | 3.28                      | 1.4 | 5.14                  | <1  | 3.22                  | 1.5 |
|           | [5.33 ± 0.02]         | [5.48 ± 0.02]             | *   | [5.29 ± 0.04]         | ns  | [5.49 ± 0.02]         | **  |
| OVSAHO    | 4.83                  | 1.02                      | 4.7 | 3.01                  | 1.6 | 1.43                  | 3.4 |
|           | [5.32 ± 0.01]         | [5.99 ± 0.03]             | *** | [5.52 ± 0.02]         | **  | [5.84 ± 0.05]         | *** |

Table S1. Effect of HDACi pretreatment on cisplatin-induced cytotoxicity.

Data shown are the mean of pooled data from at least three experiments each carried out in triplicates. Shift-factors (SF) were calculated by dividing the IC<sub>50</sub>-values without and with HDACi-preincubation. Levels of significance: ns (p > 0.05); \* ( $p \le 0.05$ ); \*\* ( $p \le 0.01$ ); \*\*\* ( $p \le 0.001$ ).





























← cisplatin
← cisplatin + 48 h 20 nM panobinostat









**Figure S1. HDACi pretreatment enhance the cytotoxic effects of cisplatin.** A2780 (a,b), CaOV3 (c,d), HEY (e,f), Kuramochi (g,h), and OVSAHO (i,j) were pretreated with the indicated HDACi 48 h prior to cisplatin (cDDP) administration. After another 72 h, IC<sub>50</sub>-values were determined by MTT-assay. Data shown are normalized to vehicle control and pooled of at least two experiments each carried out in triplicates.



**Figure S2. Pretreatment with nexturastat A in low concentrations did not enhance the cytotoxic effects of cisplatin.** HEY (a) and CaOV3 (b) cells were pretreated with the indicated HDACi 48 h prior to cisplatin (cDDP) administration. After another 72 h, IC50-values were determined by MTT-Assay. Data shown are normalized to vehicle control and pooled of two (a) or one (b) experiment each carried out in triplicates.



